Non Small Cell Lung Cancer

Why trials studying Non Small Cell Lung Cancer stopped, in this sample of ClinicalTrials.gov.

37 stopped trials with a clear reason; 86% ended for non-scientific reasons.

Trials

• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  NCT06694454 · SUSPENDED · other
  “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
  NCT06714617 · TERMINATED · funding business
  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”
• The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery
  NCT05251805 · TERMINATED · slow accrual
  “Initial observations suggest challenges in performing bone marrow aspiration in the first few patients enrolled in the study.”
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
  NCT05714553 · TERMINATED · funding business
  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
  NCT05631574 · TERMINATED · funding business
  “Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.”
• A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT05513703 · TERMINATED · funding business
  “Strategic considerations”
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
  NCT05395052 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
  NCT05141357 · TERMINATED · slow accrual
  “Slow Recruitment”
• Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
  NCT04966676 · TERMINATED · slow accrual
  “Low accrual”
• RTX-224 Monotherapy in Patients With Solid Tumors
  NCT05219578 · TERMINATED · safety
  “The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22. RTX-224 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared rapidly (w/in 10 min).”
• Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
  NCT03989050 · WITHDRAWN · logistics pi
  “Administrative reasons”
• Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
  NCT04754815 · WITHDRAWN · logistics pi
  “Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt to be clinically relevant.”
• Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy
  NCT04556435 · TERMINATED · funding business
  “Change in the sponsor's business strategy (new focus on breast cancer)”
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
  NCT04725331 · TERMINATED · funding business
  “Sponsor decision following completion of Phase I part not driven by safety reason”
• Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
  NCT04485026 · WITHDRAWN · slow accrual
  “No enrollments, low patient population as well as a dramatic change in the insurance approval processes for oligoprogressive state with eviCore saying they do not support SBRT in this setting at all.”
• XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT04622072 · TERMINATED · funding business
  “Strategic considerations”
• A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
  NCT04272203 · TERMINATED · funding business
  “Strategic considerations”
• Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab
  NCT04791215 · TERMINATED · slow accrual
  “Low accrual”
• Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
  NCT04173338 · TERMINATED · regulatory
  “Closed by IRB on 3/28/22”
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
  NCT04116320 · TERMINATED · slow accrual
  “Unable to enroll enough patients to complete targeted enrollment in a reasonable time.”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
  NCT03166254 · WITHDRAWN · funding business
  “Lost funding”
• Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
  NCT03574220 · WITHDRAWN · slow accrual
  “No accrual - closed by PRMC”
• PDX Models From EGFR Mutant Tumors
  NCT03872440 · WITHDRAWN · slow accrual
  “Did not meet the expected enrollment rate.”
• Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
  NCT03699033 · WITHDRAWN · slow accrual
  “No patients available”
• Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
  NCT03412058 · TERMINATED · slow accrual
  “The study was terminated prematurely due to insufficient patient recruitment”
• Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT03382912 · TERMINATED · safety
  “The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.”
• Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala
  NCT03209128 · TERMINATED · slow accrual
  “diffciculties to recruit patients and a lot of patients prematurely terminated”
• Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury
  NCT03632369 · WITHDRAWN · slow accrual
  “No participants were enrolled and no data was collected for the study”
• Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
  NCT02423954 · TERMINATED · logistics pi
  “Investigator no longer at site to enroll patients or write up data”
• A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
  NCT02117024 · TERMINATED · funding business
  “Sponsor Decision; strategic - based on changing treatment landscape”
• Perioperative Rehabilitation in Operation for Lung Cancer
  NCT01893580 · TERMINATED · slow accrual
  “Due to low recruiment rate, the study design is chanced to a feasibility study”
• Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
  NCT01532362 · TERMINATED · funding business
  “Drug sponsor stopped drug manufacture due to toxicity issues from other studies”
• First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
  NCT01038037 · TERMINATED · slow accrual
  “1. Very low enrollment rate. 2. Recent studies question the effect of adding panitumumab in this category of patients. 3. Too high toxicity rate”
• Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
  NCT00986284 · SUSPENDED · slow accrual
  “Lack of patients and some progressed disease soon after surgery”
• Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
  NCT00787267 · TERMINATED · slow accrual
  “Poor accrual”
• Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer
  NCT00735878 · TERMINATED · futility
  “data from a similar did not show efficacy.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.